Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia

NCT01214915 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Thrombocythemia (ET)

Interventions

DRUG: Anagrelide Hydrochloride

Sponsor

Shire